John S. Fischer was named General Counsel of Avanos Medical, Inc. As of November 6, 2026, Avanos Medical, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 30, 2026, naming 1 appointment (Form 8-K, July 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Avanos Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Avanos Medical, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-30. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Avanos Medical, Inc. files it.
Also on the record for Avanos Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.3% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 11.5% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 3.7% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 6.89% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by RGM Capital, LLC | — | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by Dimensional Fund Advisors LP | 4.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Armistice Capital, LLC | 5.39% of the class | 5%+ stakes | Source |
| October 30, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 7.38% of the class | 5%+ stakes | Source |
| October 9, 2025 | Stake report, Schedule 13G/A, by Dimensional Fund Advisors LP | 5.1% of the class | 5%+ stakes | Source |
| October 7, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 10.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Avanos Medical, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Avanos Medical, Inc. and the records around it.
Companies that share a holder
- RGM Capital, LLC also filed stake reports on 2 other companies: PagerDuty, Inc. (Feb 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Avanos Medical, Inc.
Get an email when Avanos Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Avanos Medical, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Avanos Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avanos Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-30 | In | General Counsel | 8-K, 2026-07-30 |
Who leads Avanos Medical, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- General Counsel: John S. Fischer, appointed (filed 2026-07-30).
New leaders reset buying decisions — get the Full Report on Avanos Medical, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the General Counsel at Avanos Medical, Inc., with the record behind each one.
Find candidates like General Counsel at Avanos Medical, Inc.Every change, in the filing's words
Appointed: John S. Fischer, General Counsel
The following table sets forth the name and title of each officer who was appointed: Name Title David C. Pacitti President and Chief Executive Officer Scott M. Galovan Vice President, Chief Financial Officer and Treasurer John S. Fischer General Counsel and Secretary Biographies of each of David C. Pacitti and Scott M. Galovan are set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 under the caption "Directors, Executive Officers, and Corporate Governance." John S. Fischer, age 68, was appointed as the Company's General Counsel and Secretary on July 27, 2
- Directors Pursuant to the terms of the Merger Agreement, upon, but conditioned on the occurrence of, the Effective Time, Gary D. Blackford, Dr. Lisa Egbuonu-Davis, Indrani L. Franchini, Patrick J. O'Leary, David C. Pacitti, and Julie Shimer each resigned from their positions as members of the board of directors of the Company and from any and all committees of the board of directors of the Company on which they served.
- In addition, pursuant to the terms of the Merger Agreement, from and after the Effective Time, Joel Rotroff, who was the sole director of Merger Subsidiary immediately before the Effective Time, became a director of the Surviving Corporation.
- Immediately following the Effective Time, David C. Pacitti, Scott M. Galovan and John S. Fischer were appointed to the board of directors of the Surviving Corporation and Joel Rotroff resigned from the board of directors of the Surviving Corporation.
- Officers In connection with the consummation of the Merger, all individuals serving as an officer of the Company, prior to the Effective Time, were removed from such position effective as of the Effective Time.
- Immediately following the Effective Time, Parent caused the Company to appoint each individual listed below to the office set forth opposite such individual's name.
Tools for this story
Each opens in a new tab, filled in for Avanos Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.